
Who is embecta?
embecta is a global company that develops and provides solutions that make life better for people living with diabetes. We spun off from Becton, Dickinson and Company (BD) more than three years ago.
Today, we are the leading producer of insulin injection devices in the world, making about 8 billion injection devices a year, which are used by ~30 million people in more than 100 countries. Our broad portfolio of products — complemented by education and support resources — helps people with diabetes deliver their insulin correctly.
Since the spinoff, embecta has been selling BD pen needles and insulin syringes, and over the past few months, we began rolling out the new embecta packaging. While the packaging has a new look that aligns to the embecta brand, it is the same product inside.
What will be different about the packaging?
With the spin-off to embecta, we took this as an opportunity to re-evaluate our packaging through the lens of the customer, understanding what they currently like about our packaging and where we have an opportunity to refresh and make our packaging better.
Pharmacists and people who use our products today are most familiar with the color of their box. For example, they know that the green box is the 4mm pen needle and the purple box is the 5mm. Based on this, we have kept the color of our pen needle boxes the same as they are currently. For insulin syringes, this color identifier was not in place previously, so we took this as an opportunity to align the color of the syringe boxes to the needle length, similar to the pen needles. You will also notice that for both pen needles and insulin syringes, the product name no longer includes the BD logo, so look for “Nano 2nd Gen” or “Ultra-Fine,” which is in big, bold font on the packaging.
Will patients need a new prescription or see a change to insurance coverage?
Our objective is to make this a seamless transition for patients, healthcare providers and pharmacists. As these are the same products, patients will not need a new prescription when getting a refill. We have worked to ensure that BD and embecta products will be linked in pharmacy systems for ease of dispensing based on inventory across the channel.
The embecta products are covered by insurance just as the BD products were covered. While the national reimbursement code (NRC) is changing with the change to embecta, HCPs, pharmacists and patients can be confident that insurance coverage will remain unaffected.
What’s the most important thing to know about this transition?
The most important thing to know for both our customers and the people they serve is that while the packaging has a new look, the products are the same you know and trust. Our manufacturing process and the materials used have not changed. Our products are made in the same facilities and undergo the same quality control procedures at embecta as they did under BD.
All information and claims presented in this advertisement are solely those of the manufacturer and do not reflect the views, opinions, or endorsements of McKesson Corporation or ideaShare. McKesson Corporation does not verify, endorse, or guarantee the accuracy or reliability of any information or claims made by the manufacturer.